RYSTIGGO (ROZANOLIXIZUMAB)

**Product type:** Human Prescription Drug

**Active ingredient:** ROZANOLIXIZUMAB

**Strength:** 140 mg/mL

**Dosage form:** Injection, Solution

**Route:** Subcutaneous

**Labeler:** UCB, Inc.

**Marketing category:** BLA (BLA761286)

**Pharmacologic class:** Neonatal Fc Receptor Blocker [EPC], Neonatal Fc Receptor Blockers [MoA]